Hemab Therapeutics Holdings, Inc.
COAG evidence brief
What we can confirm
- BioSniper Score:
- 7.3 / 10
- Market Cap:
- $1.84B
- Lead Asset:
- sutacimig (Phase 2)
What it means
What to watch
Prepared research question
What matters most for COAG—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · COAG
Hemab Therapeutics Holdings, Inc. (COAG) is a clinical-stage biotechnology company developing therapies for blood coagulation disorders, with a focus on Glanzmann thrombasthenia, Factor VII deficiency, and Von Willebrand Disease.
Key risk: No approved products
BioSniper Score
Based on 4 of 6 signals
Market Cap
$1.84B
Cash Runway
—
Lead Asset
sutacimig (Phase 2)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 4 clinical trials for Hemab Therapeutics Holdings, Inc..
Hemab Therapeutics Holdings, Inc. (COAG) is a clinical-stage biotechnology company developing therapies for blood coagulation disorders, with a focus on Glanzmann thrombasthenia, Factor VII deficiency, and Von Willebrand Disease.
- Cash & equivalents of $237.4M as of 2026-06-30 [sec].
- Net income of -$24.1M for the six months ended June 30, 2026 [sec].
- Shareholders' equity of $454.3M as of 2026-06-30 [sec].
- Accumulated deficit of $204.5M as of March 31, 2026 [sec_mda].
- Three ongoing Phase 1/2 or Phase 2 clinical trials for sutacimig (Glanzmann thrombasthenia, Factor VII deficiency) and HMB-002 (Von Willebrand Disease) [catalyst].
What works
- Strong cash position of $237.4M as of 2026-06-30 provides runway for ongoing clinical development [sec].
- Three product candidates in clinical trials targeting distinct bleeding disorders, diversifying pipeline risk [catalyst].
- Positive shareholders' equity of $454.3M as of 2026-06-30 indicates a solid balance sheet [sec].
What to weigh
- No approved products and heavy dependence on sutacimig and HMB-002, which are the only clinical-stage candidates [sec].
- Accumulated deficit of $204.5M as of March 31, 2026, with expectations of continued net losses [sec_mda].
- Expenses expected to increase substantially as trials advance, with no guarantee of profitability [sec].
From the filings
Quoted directly from source documents.
Accumulated deficit as of March 31, 2026
“As of March 31, 2026, we had an accumulated deficit of $204.5 million.”
SEC MD&A · May 21, 2026
Dependence on sutacimig and HMB-002
“We are heavily dependent on the success of sutacimig and HMB-002, which are our only clinical-stage product candidates.”
SEC filings · April 30, 2026
Catalyst timeline
- 2022-12-13 · Phase 2 start for HMB-001 in Glanzmann thrombasthenia — First-in-human study evaluating safety, tolerability, PK, PD, and efficacy.
- 2025-02-06 · Phase 2 start for HMB-002 in Von Willebrand Disease — Study named Velora Pioneer assessing safety, tolerability, PK, PD, and efficacy.
- 2026-03-11 · Phase 2 start for sutacimig in Factor VII deficiency — Study evaluating safety and efficacy in congenital Factor VII deficiency.
Risks & what to watch (3)›
Key risks
- No approved products — Company has no marketed products and may never develop marketable products [sec].
- Narrow pipeline dependency — Business depends heavily on sutacimig and HMB-002, the only clinical-stage candidates [sec].
- Increasing expenses and losses — Expenses expected to rise substantially with ongoing trials; accumulated deficit of $204.5M [sec_mda].
What to watch
- Progress of sutacimig Phase 1/2 trial in Glanzmann thrombasthenia and Phase 2 trial in Factor VII deficiency [catalyst].
- Progress of HMB-002 Phase 1/2 trial in Von Willebrand Disease [catalyst].
- Initiation of clinical trials for HMB-003 in heavy menstrual bleeding [sec_mda].
- Cash burn rate and any changes in accumulated deficit in future financial reports [sec].
Sources: Catalysts · SEC filings · SEC MD&A · Generated September 30, 2026 · How we verify sources →
Run Hemab Therapeutics Holdings, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Hemab Therapeutics Holdings, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.03 · 0% dilution
Lead: Phase 2
1 candidate
No upcoming catalysts tracked
16 buys · 0 sells (180d)
Pipeline
Regulatory
Financials
Frequently asked questions
What is the AI investment thesis for Hemab Therapeutics Holdings, Inc.?
Hemab Therapeutics Holdings, Inc. (COAG) is a clinical-stage biotechnology company developing therapies for blood coagulation disorders, with a focus on Glanzmann thrombasthenia, Factor VII deficiency, and Von Willebrand Disease.
What is Hemab Therapeutics Holdings, Inc.'s lead drug candidate?
Hemab Therapeutics Holdings, Inc.'s most advanced tracked candidate is sutacimig (Phase 2) for Congenital Factor VII Deficiency.
Who is the CEO of Hemab Therapeutics Holdings, Inc.?
Dr. Benny Sorensen M.D., Ph.D. is the chief executive officer of Hemab Therapeutics Holdings, Inc. (COAG).
Where is Hemab Therapeutics Holdings, Inc. headquartered?
Hemab Therapeutics Holdings, Inc. (COAG) is headquartered in Cambridge, MA, United States.
What therapeutic areas does Hemab Therapeutics Holdings, Inc. focus on?
Hemab Therapeutics Holdings, Inc. develops therapies across Hematology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.